Onward Medical N.V. ONWD
EURONEXT · Belgium · Health Technology
€2.64-0.06 (-2.40%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Onward Medical NV (ONWRF) posts EUR4.2 million in H1 2026 revenue and a EUR81.5 million cash runway into 2028, fueled by a fivefold jump in ARC-EX system sales and over EUR40 million in fresh equity.
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces its financial and operating results for the first half
EINDHOVEN, the Netherlands, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announced that it will release its first-half 2026 financial results and host a webcast with a comprehensive business update on September 9, 2026. The webcast, presented by CEO Dave Marver, will begin at 2
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.